Finanzen von PharmaCyte Biotech Inc (PMCB)PMCBPharmaCyte Biotech Inc

Evaluating the bottom line, PharmaCyte Biotech Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -57.70%, provide a clear picture of how effectively PMCB converts its operational activities into shareholder value.

In the context of the broader market, PMCB competes directly with industry leaders such as YCBD and PAVS. With a market capitalization of $3.87M, it holds a significant position in the sector. When comparing efficiency, PMCB's gross margin of N/A stands against YCBD's 50.03% and PAVS's 19.98%. Such benchmarking helps identify whether PharmaCyte Biotech Inc is trading at a premium or discount relative to its financial performance.

The latest earnings report showed a net income of -$4,873,411 for Q4 2026, continuing a trend of negative earnings. However, the forward P/E ratio is 7.02, suggesting potential undervaluation based on future earnings expectations.